Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Development of two machine learning models to predict conversion from primary HER2-0 breast cancer to HER2-low metastases: a proof-of-concept study.
Miglietta F, Collesei A, Vernieri C, Giarratano T, Giorgi CA, Girardi F, Griguolo G, Cacciatore M, Botticelli A, Vingiani A, Fotia G, Piacentini F, Massa D, Zanghì F, Marino M, Pruneri G, Fassan M, Dei Tos AP, Dieci MV, Guarneri V. Miglietta F, et al. Among authors: fotia g. ESMO Open. 2025 Jan;10(1):104087. doi: 10.1016/j.esmoop.2024.104087. Epub 2024 Dec 19. ESMO Open. 2025. PMID: 39705838 Free PMC article.
Early downmodulation of tumor glycolysis predicts response to fasting-mimicking diet in triple-negative breast cancer patients.
Ligorio F, Vingiani A, Torelli T, Sposetti C, Drufuca L, Iannelli F, Zanenga L, Depretto C, Folli S, Scaperrotta G, Capri G, Bianchi GV, Ferraris C, Martelli G, Maugeri I, Provenzano L, Nichetti F, Agnelli L, Lobefaro R, Fucà G, Fotia G, Mariani L, Morelli D, Ladisa V, De Santis MC, Lozza L, Trecate G, Belfiore A, Brich S, Bertolotti A, Lorenzini D, Ficchì A, Martinetti A, Sottotetti E, Arata A, Corsetto P, Sorrentino L, Rediti M, Salvadori G, Minucci S, Foiani M, Apolone G, Pagani M, Pruneri G, de Braud F, Vernieri C. Ligorio F, et al. Among authors: fotia g. Cell Metab. 2024 Dec 17:S1550-4131(24)00450-9. doi: 10.1016/j.cmet.2024.11.004. Online ahead of print. Cell Metab. 2024. PMID: 39694040
Molecular Characterization and Clinical Relevance of MGMT-Silenced Pancreatic Cancer.
Nichetti F, Silvestri M, Agnelli L, Franza A, Pircher C, Rota S, Ambrosini P, Fotia G, Hüllein J, Randon G, Lajer P, Perrone F, Tamborini E, Leoncini G, Coppa J, Busset MDD, Pusceddu S, Milione M, Morano F, Pietrantonio F, Pruneri G, Mazzaferro V, Lipka DB, Köhler BC, Hübschmann D, Fröhling S, de Braud F, Niger M. Nichetti F, et al. Among authors: fotia g. Cancer Med. 2024 Dec;13(23):e70393. doi: 10.1002/cam4.70393. Cancer Med. 2024. PMID: 39618336 Free PMC article.
Optimal Choice of Adjuvant Treatment for Renal Cell Carcinoma Following Nephrectomy.
Bottiglieri A, Sepe P, Stellato M, Pircher C, Fotia G, Leone AG, Guadalupi V, Claps M, Giannatempo P, Verzoni E, Procopio G. Bottiglieri A, et al. Among authors: fotia g. Cancer Manag Res. 2022 Oct 21;14:3071-3081. doi: 10.2147/CMAR.S360441. eCollection 2022. Cancer Manag Res. 2022. PMID: 36275783 Free PMC article. Review.
Outcomes of First-Line Abiraterone Acetate or Enzalutamide for Older Adults With Metastatic Castration-Resistant Prostate Cancer According to Use of Upfront Docetaxel for Metastatic Castration-Sensitive Prostate Cancer in an International Multicenter Registry: A SPARTACUSS-Meet-URO 26 Study.
Fotia G, Saieva C, Lee-Ying R, Patrikidou A, Nuzzo PV, Zanardi E, Rossetti S, Davidsohn M, Eid M, El Zarif T, McClure H, Spinelli GP, Damassi A, Murianni V, Vauchier C, Oliveira TM, Malgeri A, Modesti M, Mestre RP, Valenca L, Ravi P, Santini D, Pignata S, De Giorgi U, Sweeney C, Heng D, Procopio G, Russo A, Francini E; Spartacuss Group. Fotia G, et al. Clin Genitourin Cancer. 2024 Oct;22(5):102185. doi: 10.1016/j.clgc.2024.102185. Epub 2024 Aug 9. Clin Genitourin Cancer. 2024. PMID: 39217072 Free article.
Real World Analysis of Peritoneal Metastasis From Renal Cell Carcinoma. Meet-Uro27.
Stellato M, Buti S, Maruzzo M, Bassanelli M, Bersanelli M, Napoli MD, Dionese M, Fanelli M, Filippi R, Fotia G, Galli L, Grillone F, Maffezzoli M, Maiorano BA, Nasso C, Rebuzzi SE, Lalli L, Roviello G, Sorarù M, Vincenzi B, Procopio G, Verzoni E. Stellato M, et al. Among authors: fotia g. Clin Genitourin Cancer. 2024 Jun;22(3):102078. doi: 10.1016/j.clgc.2024.102078. Epub 2024 Mar 19. Clin Genitourin Cancer. 2024. PMID: 38631104
Docetaxel Versus Androgen-Receptor Signaling Inhibitors (ARSI) as Second-Line Therapy After Failure of First-Line Alternative ARSI for the Elderly ≥ 75 Years Old With Metastatic Castration-Resistant Prostate Cancer (mCRPC): A SPARTACUSS-Meet-URO 26 Real-World Study.
Patrikidou A, Saieva C, Lee-Ying R, Nuzzo PV, Zarif TE, McClure H, Davidsohn M, Eid M, Spinelli GP, Catalano F, Cremante M, Fotia G, Rossetti S, Valenca L, Vauchier C, Ottanelli C, Andrade L, Gennusa V, Mestre RP, Fornarini G, Pignata S, Procopio G, Santini D, Ravi P, Sweeney C, Heng D, De Giorgi U, Fizazi K, Russo A, Francini E; SPARTACUSS Group. Patrikidou A, et al. Among authors: fotia g. Clin Genitourin Cancer. 2024 Dec;22(6):102230. doi: 10.1016/j.clgc.2024.102230. Epub 2024 Oct 5. Clin Genitourin Cancer. 2024. PMID: 39461026 Free article.
Clinical outcomes of volume of disease on patients receiving enzalutamide versus abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer.
Nuzzo PV, Ravera F, Saieva C, Zanardi E, Fotia G, Malgeri A, Rossetti S, Valença LB, Oliveira TM, Vauchier C, Pereira Mestre R, Modesti M, Patrikidou A, Pignata S, Procopio G, Fornarini G, De Giorgi U, Russo A, Francini E. Nuzzo PV, et al. Among authors: fotia g. Ther Adv Med Oncol. 2023 Mar 3;15:17588359231156147. doi: 10.1177/17588359231156147. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 36895852 Free PMC article.
Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer.
Nuzzo PV, Pederzoli F, Saieva C, Zanardi E, Fotia G, Malgeri A, Rossetti S, Valenca Bueno L, Andrade LMQS, Patrikidou A, Mestre RP, Modesti M, Pignata S, Procopio G, Fornarini G, De Giorgi U, Russo A, Francini E; SPARTACUSS Investigators. Nuzzo PV, et al. Among authors: fotia g. J Transl Med. 2023 Feb 3;21(1):75. doi: 10.1186/s12967-022-03861-2. J Transl Med. 2023. PMID: 36737752 Free PMC article.
33 results